Lingkang Pharmaceutical announced that the latest conversion price of the “Lingkang Convertible Bonds” issued by the company was 6.5 yuan/share; as of August 31, 2026, the closing price of the company's stock price had been lower than 85% of the current conversion price for at least 15 out of 30 consecutive trading days, which had triggered a downward revision of the share conversion price. The board of directors of the company has reviewed and approved a proposal to revise the share conversion price downward, which still needs to be submitted to the shareholders' meeting for consideration.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.